Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology firm focused on developing innovative therapies for heart disease, has announced two significant oral presentations at the American Heart Association (AHA) 2025 Scientific Sessions, scheduled for November 7-10, 2025, in New Orleans, Louisiana. These presentations will feature key findings related to the company”s investigational gene therapy, TN-201.
The first presentation will showcase interim safety and efficacy results from the MyPEAK-1 Phase 1b/2a clinical trial, which investigates TN-201 as a potential treatment for hypertrophic cardiomyopathy (HCM) associated with myosin-binding protein C3 (MYBPC3). This condition is characterized by a deficiency of the MyBP-C protein, which is crucial for heart function.
Details for the first presentation are as follows:
- Abstract Title: TN-201, an Investigational MYBPC3 Gene Replacement Therapy: Interim Clinical Data from MyPEAK-1, a Phase Ib/2a Study Evaluating Safety and Early Efficacy of TN-201 in Adult Patients with MYBPC3-Associated Hypertrophic Cardiomyopathy
- Session Type: Late-Breaking Science: Main Event (Oral Presentation)
- Session Title: Forgotten No More: The Current Belle of the Ball? Breakthrough Evolutions in Hypertrophic Cardiomyopathy
- Presenting Author: Milind Y Desai, M.D., MBA, director of the Hypertrophic Cardiomyopathy Center at Cleveland Clinic
- Presentation Date & Time: Saturday, November 8, 2025, from 10:25 AM – 10:35 AM CT
In addition, Tenaya will present results from a preclinical study evaluating its cellular reprogramming treatment in a pig model of ischemic heart failure. This study aims to enhance cardiac function after ischemic injury by regenerating heart cells.
Details for this late-breaking presentation include:
- Abstract Title: First Demonstration of Significant and Durable Improvement of Cardiac Function in Pig Model of Ischemic Heart Failure with Direct Reprogramming Delivered Precisely to Infarct Border via Guided Intramyocardial Injection Catheter
- Session Type: Late-Breaking Basic Science (Oral Presentation)
- Session Title: Next-Generation Therapies for Ischemic Heart Repair: From Cells to Imaging
- Presenting Author: Kathy Ivey, Senior Vice President of Research, Tenaya Therapeutics
- Presentation Date & Time: Sunday, November 9, 2025, from 8:00 AM – 8:10 AM CT
Following the presentations, Tenaya management will conduct a conference call on Monday, November 10, 2025, at 8:00 AM ET/5:00 AM PT to discuss the findings from the MyPEAK-1 clinical trial. Investors and analysts can join the webcast via the investor section of Tenaya”s website at www.tenayatherapeutics.com.
About Tenaya Therapeutics
Tenaya Therapeutics is dedicated to discovering and delivering potentially curative therapies that target the underlying causes of heart disease. The company”s pipeline includes gene therapies for HCM and arrhythmogenic right ventricular cardiomyopathy (ARVC), as well as small molecule therapies aimed at treating heart failure and related conditions.
For further information, please visit www.tenayatherapeutics.com.
Media Contacts:
Michelle Corral, VP, Corporate Communications and Investor Relations, [email protected]
Wendy Ryan, Ten Bridge Communications, [email protected]
